TheEdgeResearch
Home / Stocks / RHHBY

Roche Holding AG (RHHBY)

OTC Healthcare Drug Manufacturers - General
$58.46 ▼ -0.88%
Market Cap
$373.59B
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
0.35
52-Wk Range
47.05-61.75
CEO
Thomas Schinecker
Country
CH
Currency
USD

Roche Holding AG operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Basel, BS, CH. The stock last traded at $58.46, down 0.88% on the session, giving a market capitalisation of $373.59B. On trailing twelve-month figures it carries a trailing P/E of 25.83, a net margin of 20.3%. Its beta of 0.35 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
25.83
Price / Sales
4.49
Price / Book
9.82
EV / EBITDA
13.76
Gross margin
73.3%
Operating margin
31.9%
Net margin
20.3%
Return on equity
—
Debt / equity
0.97
Current ratio
1.23
Dividend yield
2.5%
Payout ratio
68.5%
Company profile
Exchange
Other OTC
Employees
103,249
IPO date
2003-08-20
Headquarters
Basel, BS, CH
About Roche Holding AG

Roche Holding AG is a prominent global entity primarily active in the pharmaceutical and diagnostics industries. Its extensive operations encompass numerous countries, including key markets such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside a broader international presence. The company's pharmaceutical division is dedicated to developing and marketing a diverse range of medicinal products. These treatments target various therapeutic areas like oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory conditions. Additionally, their portfolio addresses specific ailments such as anemia, cancer, dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation. In the diagnostics sector, Roche supplies advanced in-vitro tests utilized for detecting and monitoring a wide array of diseases, including cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. They also provide crucial diagnostic instruments and reagents to healthcare facilities. Furthermore, Roche is engaged in a research partnership with Synlogic, Inc., focused on identifying a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). This well-established organization, founded in 1896, maintains its corporate headquarters in Basel, Switzerland.

Comparable companies

Roche Holding AG is most often compared with the following Healthcare names:

ABBVAMGNAZNGSKJNJLLYMRKNVSPFESNY
More research on RHHBY
RHHBY technical analysis RHHBY TheEdge Score Compare against peers
Open full interactive analysis & DCF →